Transplant in myeloma: who, when, and why?

2.

Sant

M

,

Minicozzi

P

,

Mounier

M

, et al;

EUROCARE-5 Working Group

.

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study

.

Lancet Oncol

.

2014

;

15

(

9

):

931

-

942

.

3.

Dimopoulos

MA

,

Moreau

P

,

Terpos

E

, et al.

Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow up

.

Hemasphere

.

2021

;

5

(

2

):

e528

.

4.

Shibata

T

,

Ikeda

Y

,

Isobe

T

,

Ota

H

,

Nimi

M.

[Prolonged survival in a case of multiple myeloma treated with high dose of melphalan]

.

Rinsho Ketsueki

.

1973

;

14

(

5

):

619

-

625

.

5.

McElwain

TJ

,

Powles

RL

.

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

.

Lancet

.

1983

;

2

(

8354

):

822

-

824

.

6.

Attal

M

,

Huguet

F

,

Schlaifer

D

, et al.

Intensive combined therapy for previously untreated aggressive myeloma

.

Blood

.

1992

;

79

(

5

):

1130

-

1136

.

7.

Fermand

JP

,

Chevret

S

,

Ravaud

P

, et al.

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients

.

Blood

.

1993

;

82

(

7

):

2005

-

2009

.

8.

Cunningham

D

,

Paz-Ares

L

,

Milan

S

, et al.

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

.

J Clin Oncol

.

1994

;

12

(

4

):

759

-

763

.

9.

Lenhoff

S

,

Hjorth

M

,

Holmberg

E

, et al.

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group

.

Blood

.

2000

;

95

(

1

):

7

-

11

.

10.

Attal

M

,

Harousseau

JL

,

Stoppa

AM

, et al.

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

.

N Engl J Med

.

1996

;

335

(

2

):

91

-

97

.

11.

Fermand

JP

,

Ravaud

P

,

Chevret

S

, et al.

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial

.

Blood

.

1998

;

92

(

9

):

3131

-

3136

.

12.

Child

JA

,

Morgan

GJ

,

Davies

FE

, et al;

Medical Research Council Adult Leukaemia Working Party

.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

.

N Engl J Med

.

2003

;

348

(

19

):

1875

-

1883

.

13.

Palumbo

A

,

Bringhen

S

,

Petrucci

MT

, et al.

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

.

Blood

.

2004

;

104

(

10

):

3052

-

3057

.

14.

Fermand

JP

,

Katsahian

S

,

Divine

M

, et al;

Group Myelome-Autogreffe

.

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

.

J Clin Oncol

.

2005

;

23

(

36

):

9227

-

9233

.

15.

Bladé

J

,

Rosiñol

L

,

Sureda

A

, et al;

Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA)

.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

.

Blood

.

2005

;

106

(

12

):

3755

-

3759

.

16.

Barlogie

B

,

Kyle

RA

,

Anderson

KC

, et al.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321

.

J Clin Oncol

.

2006

;

24

(

6

):

929

-

936

.

17.

Attal

M

,

Lauwers-Cances

V

,

Hulin

C

, et al;

IFM 2009 Study

.

Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma

.

N Engl J Med

.

2017

;

376

(

14

):

1311

-

1320

.

18.

Perrot

A

,

Lauwers-Cances

V

,

Cazaubiel

T

, et al.

Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial

.

Blood

.

2020

;

136

(

suppl 1

):

39

.

19.

Richardson

PG

,

Jacobus

SJ

,

Weller

EA

, et al;

DETERMINATION

Investigators

.

Triplet therapy, transplantation, and maintenance until progression in myeloma

.

N Engl J Med

.

2022

;

387

(

2

):

132

-

147

.

20.

Cavo

M

,

Gay

F

,

Beksac

M

, et al.

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly-diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

.

Lancet Haematol

.

2020

;

7

(

6

):

e456

-

e468

.

21.

Gay

F

,

Musto

P

,

Rota-Scalabrini

D

, et al.

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplant or carfilzomib plus lenalidomide and dexamethasone followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

.

Lancet Oncol

.

2021

;

22

(

12

):

1705

-

1720

.

doi: 10.1016/S1470-2045(21)00535-0

.

22.

Perrot

A

,

Touzeau

C

,

Lambert

J

, et al.

Efficacy and safety of Isa-KRD induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study

.

Clin Lymphoma Myeloma Leuk

. Accepted manuscript.

24

September

2024

.

23.

Broijl

E

,

San Miguel

J

,

Suzuki

K

, et al.

EMAGINE/CARTITUDE-6: a randomized phase 3 study of DVRD followed by ciltacabtagene autoleucel versus DVRD followed by autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma

.

Hemasphere

.

2023

;

7

(

suppl

):

22

-

23

.

24.

Moreau

P

,

Facon

T

,

Attal

M

, et al.

Comparison of 200 mg/m(2) melphalan and 8Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

.

Blood

.

2002

;

99

(

3

):

731

-

735

.

25.

Moreau

P

,

Harousseau

JL

,

Wijdenes

J

,

Morineau

N

,

Milpied

N

,

Bataille

R.

A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma

.

Br J Haematol

.

2000

;

109

(

3

):

661

-

664

.

26.

Bensinger

WI

,

Becker

PS

,

Gooley

TA

, et al.

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

.

Bone Marrow Transplant

.

2016

;

51

(

1

):

67

-

71

.

27.

Fenk

R

,

Schneider

P

,

Kropff

M

, et al;

West German Myeloma Study Group

.

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

.

Br J Haematol

.

2005

;

130

(

4

):

588

-

594

.

28.

Bashir

Q

,

Thall

PF

,

Milton

DR

, et al.

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

.

Lancet Haematol

.

2019

;

6

(

5

):

e266

-

e275

.

29.

Roussel

M

,

Lauwers-Cances

V

,

Macro

M

, et al.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

.

Blood

.

2022

;

139

(

18

):

2747

-

2757

.

30.

Bommier

C

,

Talbot

A

,

Harel

S

,

Cuccuini

W

,

Gérard

L

,

Arnulf

B.

Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma

.

Hematol Oncol

.

2020

;

38

(

4

):

517

-

522

.

31.

Attal

M

,

Harousseau

JL

,

Facon

T

, et al;

InterGroupe Francophone du Myélome

.

Single versus double autologous stem-cell transplantation for multiple myeloma

.

N Engl J Med

.

2003

;

349

(

26

):

2495

-

2502

.

32.

Cavo

M

,

Tosi

P

,

Zamagni

E

, et al.

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

.

J Clin Oncol

.

2007

;

25

(

17

):

2434

-

2441

.

33.

Mai

EK

,

Benner

A

,

Bertsch

U

, et al.

Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial

.

Br J Haematol

.

2016

;

173

(

5

):

731

-

741

.

34.

Stadtmauer

EA

,

Pasquini

MC

,

Blackwell

B

, et al.

Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial

.

J Clin Oncol

.

2019

;

37

(

7

):

589

-

597

.

35.

Leypoldt

LB

,

Tichy

D

,

Besemer

B

, et al.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma

.

J Clin Oncol

.

2024

;

42

(

1

):

26

-

37

.

36.

Touzeau

C

,

Perrot

A

,

Hulin

C

, et al.

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

.

Blood

.

2024

;

143

(

20

):

2029

-

2036

.

37.

Moreau

P

,

Hulin

C

,

Perrot

A

, et al.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

.

Lancet Oncol

.

2024

;

25

(

8

):

1003

-

1014

.

38.

Voorhees

PM

,

Sborov

DW

,

Laubach

J

, et al.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation- eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

10

):

e825

-

e837

.

39.

Rodriguez-Otero

P

,

Moreau

P

,

Dimopoulos

MA

, et al.

Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the PERSEUS trial

.

J Clin Oncol

.

2024

;

42

(

suppl 16

):

7502

.

40.

Goldschmidt

H

,

Mai

EK

,

Bertsch

U

, et al.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label multicentre, randomised, active- controlled, phase 3 trial

.

Lancet Haematol

.

2022

;

9

:

e810

-

821

.

41.

Perrot

A

,

Lauwers-Cances

V

,

Touzeau

C

, et al.

Daratumumab plus ixazomib, lenalidomide, and dexamethasone as extended induction and consolidation followed by lenalidomide maintenance in standard-risk transplant- eligible newly diagnosed multiple myeloma patients (IFM 2018-01)

.

Blood

.

2021

;

138

(

suppl S1

):

464

.

42.

Gay

F

,

Roeloffzen

W

,

Dimopoulos

MA

, et al.

Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients

.

Blood

.

2023

;

142

(

suppl 1

):

4

.

43.

Kaiser

MF

,

Hall

A

,

Walker

K

, et al.

Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma

.

J Clin Oncol

.

2023

;

41

(

23

):

3945

-

3955

.

44.

Costa

LJ

,

Chhabra

S

,

Medvedova

E

, et al.

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

11

):

e890

-

e901

.

45.

Sive

J

,

Cuthill

K

,

Hunter

H

, et al;

British Society of Haematology

.

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

.

Br J Haematol

.

2021

;

193

(

2

):

245

-

268

.

46.

Dhakal

B

,

Shah

N

,

Kansagra

A

, et al.

ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma

.

Transplant Cell Ther

.

2022

;

28

(

6

):

284

-

293

.

47.

Rajkumar

SV

.

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

.

Am J Hematol

.

2022

;

97

(

8

):

1086

-

1107

.

48.

Wang

J

,

Shen

N

,

Shen

X

, et al.

Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease

.

Ann Med

.

2023

;

55

(

2

):

2281657

.

49.

Fernández de Larrea

C

,

Kyle

R

,

Rosiñol

L

, et al.

Primary plasma cell leukemia: consensus definition by the international Myeloma Working Group according to peripheral blood plasma cell percentage

.

Blood Cancer J

.

2021

;

11

(

12

):

192

.

50.

Kansagra

A

,

Gonsalves

WI

,

Gertz

MA

, et al.

Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma

.

Biol Blood Marrow Transplant

.

2018

;

24

(

10

):

2127

-

2132

.